Multifunctional albumin-based hydrogel/microglia composites enhancing the therapeutic potential of neonatal microglia in complex spinal cord injuries and sealing dural rupture

Treatment for spinal cord injuries (SCIs) remains largely ineffective, with scar formation and neural degeneration being major barriers to functional recovery. Neonatal microglia have shown potential in reducing scar formation and promoting axonal regrowth. However, cell viability and retention at the injury site are often suboptimal. The hostile post-SCI inflammatory microenvironment leads to poor cell survival and the dural damage that is frequently associated with SCIs results in cell loss. To address these challenges, we have developed an albumin-based hydrogel. This hydrogel creates a favorable microenvironment for the encapsulated cells, mimicking the extracellular matrix and enhancing the viability of the transplanted cells. In vivo studies demonstrate its efficacy in preventing scar formation, promoting axonal regeneration, and sealing the dura. Importantly, this hydrogel leverages albumin, a natural polymer in the body, and is synthesized through a simple process, making it highly feasible for clinical translation. In summary, this albumin hydrogel is a valuable delivery vehicle that enhances the therapeutic potential of neonatal microglia in treating SCIs, particularly those involving dural rupture.